The significant drop in Calidi Biotherapeutics' stock price is directly attributed to the announcement of a public offering, which typically leads to dilution of existing shares. The immediate negative reaction from the market reflects concerns over dilution and the impact on shareholder value. Given the size of the offering relative to the company's market cap and the steep price decline, this news is highly relevant and important to investors, with a high confidence level in the analysis.